Sleep Research Society

Sleep experts call for end of seasonal time changes ahead of ’springing forward‘

Retrieved on: 
Monday, February 26, 2024

The American Academy of Sleep Medicine urges policymakers to prioritize the well-being of individuals by abolishing seasonal time changes in favor of permanent standard time.

Key Points: 
  • The American Academy of Sleep Medicine urges policymakers to prioritize the well-being of individuals by abolishing seasonal time changes in favor of permanent standard time.
  • The AASM is joined by members of the Coalition for Permanent Standard Time in this effort to "ditch daylight saving time” and restore permanent standard time.
  • Set clocks ahead one hour in the early evening on March 9 and then go to sleep at your normal bedtime that evening.
  • For more information about daylight saving time and to find additional resources from the AASM about sleep disorders, treatments and sleep health, visit SleepEducation.org .

New position statement supports permanent standard time

Retrieved on: 
Tuesday, October 31, 2023

DARIEN, Ill., Oct. 31, 2023 (GLOBE NEWSWIRE) -- An updated position statement from the American Academy of Sleep Medicine supports the replacement of daylight saving time with permanent standard time.

Key Points: 
  • DARIEN, Ill., Oct. 31, 2023 (GLOBE NEWSWIRE) -- An updated position statement from the American Academy of Sleep Medicine supports the replacement of daylight saving time with permanent standard time.
  • “Permanent standard time is the optimal choice for health and safety.”
    The position statement was published as an accepted paper Oct. 31 in the Journal of Clinical Sleep Medicine, the official publication of the AASM.
  • The original position statement published by the AASM in 2020 stated that current evidence best supports the adoption of year-round standard time.
  • Based on a growing body of evidence, the updated position statement emphasizes that daylight saving time should be replaced by permanent standard time.

Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Wednesday, August 9, 2023

DUBLIN, Ireland, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a corporate update and announced its financial results for the second quarter ended June 30, 2023.

Key Points: 
  • ET --
    DUBLIN, Ireland, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a corporate update and announced its financial results for the second quarter ended June 30, 2023.
  • Recognized $1.5 million in net product revenues for the second quarter 2023.
  • R&D expenses were $4.2 million in the quarter ended June 30, 2023, compared to $4.5 million for the same period in 2022.
  • SG&A expenses were $46.8 million in the quarter ended June 30, 2023, compared to $21.8 million for the same period in 2022.

Data Presented at the 2023 SLEEP Annual Meeting Strengthens Evidence for ProSomnus Precision Oral Appliance Therapy for the Treatment of Obstructive Sleep Apnea

Retrieved on: 
Thursday, June 8, 2023

Prior research importantly demonstrates that SASHB is predictive of mortality, cardiovascular events, and overall health outcomes, whereas the frequency-based index (apnea hypopnea index “AHI”) is not.

Key Points: 
  • Prior research importantly demonstrates that SASHB is predictive of mortality, cardiovascular events, and overall health outcomes, whereas the frequency-based index (apnea hypopnea index “AHI”) is not.
  • In this retrospective analysis of 48 patients, precision OAT demonstrated 90% therapeutic efficacy using the risk based SASHB index.
  • “As the CPAP recall persists, two abstracts investigate FDA adverse event reports and the safety of precision OAT.
  • This research further establishes ProSomnus precision OAT as a safe and efficacious treatment for OSA.”

Defined Research To Present Results From Pioneering CBD Clinical Trial For Insomnia At Sleep 2023 Medical Conference

Retrieved on: 
Thursday, June 8, 2023

Defined Research, Inc. , a science-based wellness company announces the results of its clinical trial for Defined Sleep, a proprietary oral cannabidiol (CBD)-based formula.

Key Points: 
  • Defined Research, Inc. , a science-based wellness company announces the results of its clinical trial for Defined Sleep, a proprietary oral cannabidiol (CBD)-based formula.
  • This CBD-terpene formulation resulted in an increase in both the percentage of time and the absolute time that participants spent in slow wave sleep (SWS) and REM sleep.
  • Defined Research is presenting the results from the clinical trial at Sleep 2023 , a joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society.
  • The double-blind, placebo-controlled, randomized, crossover trial ( preprint available ) of Defined Research’s patent-pending formula, Defined Sleep , is believed to be an industry-first.

Inspire Medical Systems, Inc. Announces Events at SLEEP 2023, the 37th Annual Meeting of the Associated Professional Sleep Societies

Retrieved on: 
Monday, June 5, 2023

SLEEP 2023 is the 37th annual meeting of the Associated Professional Sleep Societies (APSS), a joint venture of the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS).

Key Points: 
  • SLEEP 2023 is the 37th annual meeting of the Associated Professional Sleep Societies (APSS), a joint venture of the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS).
  • “We are thrilled to return to SLEEP and highlight our recent innovative technology enhancements to the Inspire platform and share compelling clinical data further demonstrating the real-world efficacy of our treatment,” said Tim Herbert, President and CEO.
  • There will be multiple sessions at SLEEP highlighting the outcomes of Inspire therapy, including the Year In Review and Alternative Therapies for Sleep Apnea on Saturday, June 3rd.
  • 2:45 – 3:00 pm: Patient-Reported Experience with Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea – Influence of Symptom Improvements (Marcel Braun, PhD, et al.)

Zevra Therapeutics Presents Design of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) at Beyond Sleepy 2023

Retrieved on: 
Saturday, June 3, 2023

CELEBRATION, Fla., June 03, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly Zevra.), a rare disease therapeutics company, today announced that an oral presentation featuring the Phase 2 clinical trial design evaluating KP1077 as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, will be presented at the Hypersomnia Foundation’s 2023 Beyond Sleepy Conference being held June 2 - 4, 2023, in Indianapolis, IN, for people living with IH, narcolepsy and Kleine-Levin syndrome and their supporters. Zevra is a corporate sponsor of the Hypersomnia Foundation and the Beyond Sleep program.

Key Points: 
  • CELEBRATION, Fla., June 03, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly Zevra.
  • Zevra is a corporate sponsor of the Hypersomnia Foundation and the Beyond Sleep program.
  • SDX was recently granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of IH.
  • Zevra has also opened an IND to study KP1077 for the treatment of narcolepsy.

Axsome Therapeutics to Present New Sunosi® Data at SLEEP 2023

Retrieved on: 
Thursday, June 1, 2023

NEW YORK, June 01, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced presentations on Sunosi® (solriamfetol) at SLEEP 2023, the annual meeting of the American Academy of Sleep Medicine and the Sleep Research Society, being held in Indianapolis, Ind., from June 3-7, 2023.

Key Points: 
  • NEW YORK, June 01, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced presentations on Sunosi® (solriamfetol) at SLEEP 2023, the annual meeting of the American Academy of Sleep Medicine and the Sleep Research Society, being held in Indianapolis, Ind., from June 3-7, 2023.
  • The presentations include new data from the SHARP (Solriamfetol’s Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled) study in patients with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA), demonstrating sustained improvement with Sunosi on measures of cognition across 8-hours with once daily dosing.
  • Additional new data and analyses include real-world data from OSA patients taking Sunosi as part of the SURWEY study in Germany, healthcare resource use in OSA patients with residual EDS, and effect sizes and numbers needed to treat analyses.
  • “Cognitive impairment is a substantial burden to many patients with EDS and OSA.

Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ at SLEEP 2023

Retrieved on: 
Wednesday, May 31, 2023

DUBLIN, May 31, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced new data supporting the clinical profile for LUMRYZ™ (sodium oxybate) for extended-release oral suspension (CIII) and patient preference for a once-nightly oxybate in 12 abstracts, including six oral presentations, at SLEEP 2023, the 37th annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society, being held from June 3-7, 2023 in Indianapolis.

Key Points: 
  • DUBLIN, May 31, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced new data supporting the clinical profile for LUMRYZ™ (sodium oxybate) for extended-release oral suspension (CIII) and patient preference for a once-nightly oxybate in 12 abstracts, including six oral presentations, at SLEEP 2023, the 37th annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society, being held from June 3-7, 2023 in Indianapolis.
  • LUMRYZ was granted U.S. Food and Drug Administration (FDA) approval in May 2023, and is the first and only FDA approved once-at-bedtime oxybate for people living with narcolepsy.
  • “We are thrilled to attend SLEEP 2023 and present a broad range of data further supporting the clinical value proposition of LUMRYZ as a once-nightly option to manage EDS and cataplexy in narcolepsy, including data from our RESTORE and REST-ON trials,” said Jennifer Gudeman, PharmD, Senior Vice President, Medical and Clinical Affairs of Avadel.
  • LUMRYZ is available only through a restricted program under a Risk Evaluation and Mitigation Strategy called the LUMRYZ REMS.

LifeQ Introduces First-Of-Its-Kind 24-Hour Sleep Solution, Enabling Clinicians to Improve Patient Sleep Quality and Long-Term Health

Retrieved on: 
Thursday, May 18, 2023

ATLANTA, May 18, 2023 /PRNewswire/ -- LifeQ, the company that uses globally-recognized watch brands to gather personalized, clinical-grade data, unveiled a groundbreaking new sleep solution for clinicians and patients, helping uncover sleep disorders, achieve greater sleep quality, and improve health and wellness. LifeQ co-founders Laurence (Laurie) Olivier, CEO and Dr. Franco du Preez, Chief Science Officer, and Dr. Irshaad Ebrahim, Chief Sleep Officer, made the announcement.

Key Points: 
  • LifeQ will present its wearable-derived sleep solutions to the sleep clinician community at the American Academy of Sleep Medicine (AASM) and Sleep Research Society (SRS)'s SLEEP 2023 Annual Meeting from June 3-7, 2023 at Booth #333.
  • "Sleep clinicians know that sleep forms an integral part of health, and sleep quality is especially important as it directly impacts all aspects of life," stated Dr. Du Preez.
  • "LifeQ's new 24-hour Sleep Health solution offers more than 40 sleep metrics and therefore gives unprecedented insight into sleep health.
  • Each cycle usually starts with light sleep, followed by deep sleep, REM sleep, and ends with a brief period awake.